Absence of severe neonatal ABO hemolytic disease at Intermountain Healthcare. Why?

Article metrics

  • 15 Accesses

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Christensen RD, Baer VL, MacQueen BC, O’Brien EA, Ilstrup SJ. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. J Perinatol. 2018;38:517–25.

  2. 2.

    Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006;117:e855–62.

Download references

Author information

Correspondence to Whitley Hulse.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baer, V.L., Hulse, W., Bahr, T.M. et al. Absence of severe neonatal ABO hemolytic disease at Intermountain Healthcare. Why?. J Perinatol (2019) doi:10.1038/s41372-019-0553-0

Download citation